Sibutramine
Aliases: Meridia, Siredia, Reductil, Sibutrex
Summary
Sibutramine was withdrawn from most markets in 2010 due to increased risk of cardiovascular events (heart attack and stroke), particularly in patients with pre-existing cardiovascular disease. It is a centrally acting appetite suppressant that acts as a prodrug, metabolized to more potent active metabolites (M1 and M2) with longer half-lives. Unlike amphetamines, it does not cause monoamine release and does not produce euphoria.
Dose Information
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset |
|---|---|---|---|---|
| Oral | 1-2 hrs | 1-2 hrs | 3-6 hrs | 12-24 hrs |
Effect Profile
Scores (1–10) curated from multiple sources:
- Effect keyword matching from PsychonautWiki catalog
- Weighted by importance: core (×3), major (×2), minor (×1)
Moderate stimulation and anxiety/jitters with low euphoria
Tolerance
Tolerance Decay
Robust human tolerance kinetics are not well characterized. Anecdotally, some loss of appetite-suppressing effect occurs over weeks with daily use and partially reverses over several weeks of abstinence. Data quality is low; model provided for harm-reduction planning rather than precise prediction.
Cross-Tolerances
Effects
- Stimulation
- Increased energy
- Pain Relief
- Muscle Relaxation
- Increased heart rate
- Increased blood pressure
- Dry mouth
- Insomnia
- Nausea
- Headache
- Alertness enhancement
- Reduced anxiety
- Anxiety suppression
- Cognitive euphoria
- Dream potentiation
- Anxiety
- Dizziness
- Constipation
- Drowsiness
- Talkativeness
- Increased music appreciation
- Appetite suppression
- Light sensitivity
- Double vision
- Disinhibition
- Acuity suppression
- Visual acuity suppression
- Dulled perception
- Internal hallucination
- Perception of bodily heaviness